UK trial finds dexamethasone significantly reduces COVID mortality

In March 2020, the RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Since then over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.

On 16 June 2020, Chief Investigators released a statement announcing preliminary results of the dexamethasone arm finding it reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19.

Read the full statement here.

Find out more about the RECOVERY trial at: